We are organizing a group buy now for a PROTAC androgen receptor degrader and a highly selective estrogen receptor beta agonist. Everyone is welcome to join. The combination of these two compounds should give hair regrowth comparable to traditional mtf regimens but without the sexual side effects. I will start with a brief overview of how each of these compounds work.
ARV-110 is a potent PROTAC. It recruits the AR (androgen receptor) to the E3 ubiquitan ligase promting its degradation so that DHT cannot bind to it. This is temporary because new receptors are generated, but until that happens it eliminates AR activation. This is the first step that's required to treat hair loss. Kintor is currently developing a similar PROTAC to treat Androgenetic Alopecia, and they expect it to have no side effects.
WAY-200070 is a potent and selective ERβ (estrogen receptor beta ) agonist. It binds to ERβ without binding to ERα (estrogen receptor alpha) except at very high doses. This is perfect for us because ERβ is believed to mediate 17β-estradiol-induced hair growth, and does not have any feminizing effects. Things like breast growth and fat distribution etc., are believed to be controlled by ERα. ERβ activation actually silences ERα so it is expected to have the opposite effect and actually reduce or inhibit gyno while still promoting hair growth.
We have seen tremendous hair regrowth, and in some cases complete reversal of hair loss in male to female transgenders who use potent AR antagonists combined with 17β-estradiol. CIS men can't do that of course because the side effects are unacceptable. These two new compounds are available to us now and should allow us to reproduce the hair growth results of such feminizing treatments without the feminization aspect. Here are some of the examples of hair growth from using estrogen and potent AR antagonists, and what type of regrowth is expected from the combination of these two compounds at the proper dose.
View attachment 169266View attachment 169265View attachment 169264View attachment 169263View attachment 169262View attachment 169261
WAY-200070 is already being used by a handful of people on discord and they are reporting new vellus hairs in their temples. The people currently trialing are using concentrations between .1-.5% and applying it once to twice daily. The only side effects noted so far are hives/rash at the site of application in some and better skin generally. Now we are ordering more WAY-200070, and getting ARV-110 to go with it for the perfect combination. ARV-110 is being developed for castration resistant prostate cancer. The oral dose is 280-420mg daily, and almost totally suppresses the AR systemically at that dose. We will use just a small fraction of that dose topically. No one can guarantee what dose is safe and effective for either of these compounds, but most of us on discord are planning to use ARV-110 at .1% once a week. It has a 110 hour half-life so daily dosing is unnecessary. That's just 1mg/ml, or approximately 1/2000th of the oral dose for prostate cancer. Oral bioavailability is estimated at 25%. We estimate that only 5% of the topical dose will be absorbed systemically. That would give a systemic concentration that is 1/10,000th the concentration used in trials to shutdown the AR. This dose should not give any side effects. Personally I plan to use it daily so that I can just mix it together with WAY-200070. I will still use a concentration of .05-.1%, so I will be using more than others, about 7-14mg per week. Even this dose will give a systemic concentration that is around 1/700th that required to silence the AR systemically. One mg or less is impossible for most people to measure, so a stock solution may be required if you're using smaller and infrequent doses.
Here I will post further information on both compounds. ARV-110 has a large molecular weight of 812 Daltons so DMSO or microneedling will be required for topical absorption, but the large weight also helps to limit systemic absorption. At an oral dose of 35mg daily no adverse events were reported.
ARV-110 Phase 1/2 Dose Escalation: Interim Update
View attachment 169272
WAY-200070 is 67-fold more selective for ERβ over ERα. Erteberal has been trialed in humans for schizoprhenia at up to 150mg orally, and no sexual side effects were noted, leaving them to conclude that the doses used do not activate ERα. Since it's about 10x less potent there should be no activation of ERα at 15mg daily doses of WAY-200070. I am currently using this dose.
View attachment 169273
Price:
WAY-200070 is $130/g. Must order in increments of 1g.
ARV-110 is $130/200mg. Must order in increments of 200mg.
Shipping is $55 with a reship policy if your order is not received.
If you would like to participate in this group buy let us know here.
